Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00515372 · ClinicalTrials.gov registry record · Phase 1
Depression Treatment and Screening in Ovarian Cancer Patients
A Phase 1 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 409
- Enrollment target
- 1
- Study location
NCT00515372 is a Phase 1 study of Ovarian Cancer and Fallopian Tube Cancer that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 409 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00515372, a Phase 1 study of Ovarian Cancer and Fallopian Tube Cancer, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 409 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this behavioral research study is to find a quick and effective way to identify depression in patients with ovarian, peritoneal, or fallopian tube cancer. Another goal of this study is to compare an intervention program with "enhanced" standard care to see which may be more effective in improving quality of life for these patients.
Conditions Studied
Interventions
- OTHER Usual Care
- OTHER Telephone Counseling
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 409 participants |
| Start Date | 2002-12-20 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00515372
The ClinicalTrials.gov registry entry for NCT00515372 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 409 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (44% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Usual Care is the first listed.
NCT00515372 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00515372 about?
NCT00515372 is a clinical study titled "Depression Treatment and Screening in Ovarian Cancer Patients". The goal of this behavioral research study is to find a quick and effective way to identify depression in patients with ovarian, peritoneal, or fallopian tube cancer. Another goal of this study is to compare an intervention program with "enhanced" standard care to see which may be more effective in ...
What is the current status of trial NCT00515372?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 409 participants. The study started on 2002-12-20. Estimated completion is 2027-12-31.
What conditions does trial NCT00515372 study?
This clinical trial studies the following conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer.
What interventions are being tested in trial NCT00515372?
The interventions under investigation include: Usual Care (OTHER), Telephone Counseling (OTHER).
Who is sponsoring clinical trial NCT00515372?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00515372 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.